Veracyte
Veracyte Aims to Broaden Reach of Decipher Prostate Assay as Studies Continue to Expand Utility
Premium
The company reported significant momentum in test volumes for the second quarter of this year as new publications shore up utility evidence and open new applications.
Veracyte Q2 Revenues More Than Double on Test Volume Spike
The company's commercial test volume and test revenues were both up more than 200 percent compared to the same quarter last year.
The firm also shared validation data at ASCO 2021 on its nasal swab classifier to help guide treatment decisions for patients with indeterminate lung nodules.
Veracyte Bladder Cancer Test Receives Medicare Coverage
The patient must be a candidate for multiple potential treatments with varying levels of intensity or multiple therapies.
Veracyte to Acquire HalioDx for €260M
Veracyte said the acquisition will help accelerate its in vitro diagnostic test development and manufacturing operations in Europe.
Feb 17, 2021
Veracyte Q4 2020 Revenues Rise 16 Percent
Aug 5, 2020
Veracyte Prices $180M Public Stock Offering
Jul 30, 2020